Thomas Heinzen

Thomas Heinzen asked about the high awareness of the AdvanceAD-Tx (ADTX) test in the field, the sales team's strategy for approaching dermatologists, and factors contributing to rapid KOL awareness.

Answer

Derek Maetzold, Founder, President, and CEO of Castle Biosciences, confirmed high interest and enthusiasm for AdvanceAD-Tx. He detailed the limited access launch in late November 2025 to approximately 150 dermatological accounts, primarily early adopters of gene expression profile testing, noting that over half ordered at least one test in the first five weeks, with over 500 orders by mid-February. He explained the sales force compensation strategy, initially 100% focused on DecisionDx-Melanoma with ADTX volume kickers, shifting to a 90/10 split in Q2 2026, to control access, maintain melanoma momentum, ensure seamless lab/logistics, and monitor ASP growth.

Thomas Heinzen asked about the high awareness of the AdvanceAD-Tx (ADTX) test in the field, the sales team's strategy for approaching dermatologists, and factors contributing to rapid KOL awareness.

Answer

Derek Maetzold, Founder, President, and CEO of Castle Biosciences, confirmed high interest and enthusiasm for AdvanceAD-Tx. He detailed the limited access launch in late November 2025 to approximately 150 dermatological accounts, primarily early adopters of gene expression profile testing, noting that over half ordered at least one test in the first five weeks, with over 500 orders by mid-February. He explained the sales force compensation strategy, initially 100% focused on DecisionDx-Melanoma with ADTX volume kickers, shifting to a 90/10 split in Q2 2026, to control access, maintain melanoma momentum, ensure seamless lab/logistics, and monitor ASP growth.